Spots Global Cancer Trial Database for MR-based Hypofractionated Adaptive IGRT of Prostate Cancer (M-base HyPro 2.0)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: MR-based Hypofractionated Adaptive IGRT of Prostate Cancer (M-base HyPro 2.0)

Official Title: Single-arm Phase (II) Study on MR-based Hypofractionated Adaptive Image-guided Radiation Therapy for Prostate Cancer

Study ID: NCT03880851

Conditions

Prostate Cancer

Interventions

Plan adaptation of Radiation Treatment in case of anatomical changes

Study Description

Brief Summary: Single-centre single-armed, non-randomized interventional phase II-study of hypofractionated image-guided radiotherapy "IGRT" with weekly magnetic resonance imagings "MRI" for personalized adaptation of the treatment plan depending on individual MR-anatomy of prostate/organ at risks "OAR" during course of IGRT.

Detailed Description: IGRT-schedule: 20 fractions to a total dose of 60 Gy Personalized adaption of treatment plan dependning on volume-/ and constraint-thresholds and evaluation of biomarkers (multiparametric MRI, blood, tissue, stool, urine). Treatment at MR-Linac allowed